CALYXT INC (CLXT) Stock Price & Overview

NASDAQ:CLXT • US13173L2060

Current stock price

6.3 USD
+0.33 (+5.53%)
At close:
6.99 USD
+0.69 (+10.95%)
After Hours:

The current stock price of CLXT is 6.3 USD. Today CLXT is up by 5.53%. In the past month the price increased by 99.37%. In the past year, price increased by 107.37%.

CLXT Key Statistics

52-Week Range1.25 - 7.77
Current CLXT stock price positioned within its 52-week range.
1-Month Range2.97 - 7.77
Current CLXT stock price positioned within its 1-month range.
Market Cap
31.334M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.04
Dividend Yield
N/A

CLXT Stock Performance

Today
+5.53%
1 Week
+28.05%
1 Month
+99.37%
3 Months
+43.18%
Longer-term
6 Months +262.28%
1 Year +107.37%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CLXT Stock Chart

CALYXT INC / CLXT Daily stock chart

CLXT Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CLXT. When comparing the yearly performance of all stocks, CLXT is one of the better performing stocks in the market, outperforming 97.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CLXT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CLXT. CLXT has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CLXT Earnings

Next Earnings DateAug 2, 2023
Last Earnings DateMay 1, 2023
PeriodQ1 / 2023
EPS Reported-$1.09
Revenue Reported
EPS Surprise -78.10%
Revenue Surprise -99.18%

CLXT Forecast & Estimates

8 analysts have analysed CLXT and the average price target is 36.98 USD. This implies a price increase of 486.9% is expected in the next year compared to the current price of 6.3.

For the next year, analysts expect an EPS growth of 82.92% and a revenue growth 38.59% for CLXT


Analysts
Analysts47.5
Price Target36.98 (486.98%)
EPS Next Y82.92%
Revenue Next Year38.59%

CLXT Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

CLXT Financial Highlights

Over the last trailing twelve months CLXT reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -289.74% compared to the year before.


Income Statements
Revenue(TTM)167.00K
Net Income(TTM)-16.67M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-678.57%
Sales Q2Q%31.25%
EPS 1Y (TTM)-289.74%
Revenue 1Y (TTM)-99.23%

CLXT Ownership

Ownership
Inst Owners0.01%
Shares4.97M
Float2.34M
Ins Owners507.02%
Short Float %N/A
Short RatioN/A

About CLXT

Company Profile

CLXT logo image Calyxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Roseville, Minnesota and currently employs 25 full-time employees. The company went IPO on 2017-07-20. Calyxt, Inc. is a plant-based synthetic biology company. The firm is focused on research and development, including gene editing, plant breeding, and trait development. The company specializes in engineering plant metabolisms. The firm leverages its PlantSpring technology platform to engineer plant metabolism to produce sustainable materials and products for use in helping customers meet. The firm operates through the development and commercialization of products derived from plant cells. Its platform provides plant-based synthetic biology solutions to customers across multiple industries. The firm has engineered plant metabolism into products including soybeans with improved fatty-acid profiles and alfalfa able to be better digested by livestock. Its product pipeline includes hemp, winter oats, and high saturated fat soybeans. Hemp serves a range of varieties of materials science needs, including strengthening plastics and reducing petroleum-based content.

Company Info

IPO: 2017-07-20

CALYXT INC

2800 Mount Ridge Rd

Roseville MINNESOTA 55113 US

CEO: Yves Ribeill

Employees: 25

CLXT Company Website

Phone: 16516832807.0

CALYXT INC / CLXT FAQ

Can you describe the business of CALYXT INC?

Calyxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Roseville, Minnesota and currently employs 25 full-time employees. The company went IPO on 2017-07-20. Calyxt, Inc. is a plant-based synthetic biology company. The firm is focused on research and development, including gene editing, plant breeding, and trait development. The company specializes in engineering plant metabolisms. The firm leverages its PlantSpring technology platform to engineer plant metabolism to produce sustainable materials and products for use in helping customers meet. The firm operates through the development and commercialization of products derived from plant cells. Its platform provides plant-based synthetic biology solutions to customers across multiple industries. The firm has engineered plant metabolism into products including soybeans with improved fatty-acid profiles and alfalfa able to be better digested by livestock. Its product pipeline includes hemp, winter oats, and high saturated fat soybeans. Hemp serves a range of varieties of materials science needs, including strengthening plastics and reducing petroleum-based content.


Can you provide the latest stock price for CALYXT INC?

The current stock price of CLXT is 6.3 USD. The price increased by 5.53% in the last trading session.


Does CLXT stock pay dividends?

CLXT does not pay a dividend.


What is the ChartMill technical and fundamental rating of CLXT stock?

CLXT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What do analysts say about CALYXT INC (CLXT) stock?

8 analysts have analysed CLXT and the average price target is 36.98 USD. This implies a price increase of 486.9% is expected in the next year compared to the current price of 6.3.


What is CALYXT INC worth?

CALYXT INC (CLXT) has a market capitalization of 31.33M USD. This makes CLXT a Nano Cap stock.